Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilities

11. maj 2026 opdateret af: Byron Lai, University of Alabama at Birmingham
This phase II RCT evaluates the efficacy of a telehealth-delivered extended reality (XR) exergaming intervention on physical activity, cardiometabolic health, and physical fitness in physically inactive children with cerebral palsy (ages 10 to 17). A total of 130 participants will be randomized to either a 12-week XR exergaming intervention with behavioral coaching or a non-intervention control group, followed by a 24-week sustainability phase. Aim 1 examines immediate and sustained effects on physical activity levels. Aim 2 tests effects on cardiometabolic health indicators including blood lipids, blood pressure, and glycemic markers. Aim 3 explores effects on physical fitness and perceived health. All procedures are conducted remotely via telehealth.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

130

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Byron Lai, MS, PhD
  • Telefonnummer: 89725 205-638-9790
  • E-mail: blai@uabmc.edu

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35233
        • University of Alabama at Birmingham
        • Kontakt:
          • Byron Lai, MS, PhD
          • Telefonnummer: 89725 205-638-9790
          • E-mail: blai@uabmc.edu
      • Birmingham, Alabama, Forenede Stater, 32533
        • Children's of Alabama
        • Kontakt:
          • Byron Lai, MS, PhD
          • Telefonnummer: 89725 205-638-9790
          • E-mail: blai@uabmc.edu

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  1. medical diagnosis of cerebral palsy
  2. between the ages of 10-17 years (10 years of age is the minimum requirement of the Meta Quest 3s headset, as noted by the manufacturer)
  3. physician clearance to participate in moderate-intensity exercise
  4. access to a Wi-Fi Internet connection in the home
  5. a caregiver that is committed to supporting the child with setting up and assisting with the prescribed exergaming and managing the study activities

Exclusion Criteria:

  1. physically active (defined as ≥150 minutes per week of moderate-to-vigorous intensity exercise in a typical week)
  2. prone to photosensitive seizures
  3. a classification of GMFCS level V, which we have found to preclude the ability to use the Oculus Quest hand-held controllers
  4. complete blindness or deafness
  5. unable to communicate in English (participant and caregiver)

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Enkelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Extended Reality Gaming (XRG)
Immediate start of extended reality exercise program for 36 weeks.
Seated arm exercise using an extended reality headset for 36 weeks.
Ingen indgriben: Non-intervention Control
Continue habitual activities for 36 weeks.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Godin Leisure Time Exercise Questionnaire
Tidsramme: week 0, week 6, week 12, week 24, week 36
The GLTEQ is a 7-day recall survey. The GLTEQ will be scored using a health contribution (HC) score, which equates an HC score of ≥24 to the minimum aerobic guideline of 150 mins/week of moderate exercise.
week 0, week 6, week 12, week 24, week 36
Daily Step Count
Tidsramme: weeks 0-36
Steps per day, captured using the Polar Unite wrist watch.
weeks 0-36

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Changes in C-reactive Protein (hsCRP)
Tidsramme: week 0, week 6, week 12, week 24, week 36
hsCRP (mg/L) is a critical marker of inflammation that contributes to pro-inflammatory and pro-thrombotic elements of CVD risk. A single hsCRP measure is a strong predictor of myocardial infarction or coronary heart disease mortality, and several other diseases of the circulatory system in people without a history of such conditions.
week 0, week 6, week 12, week 24, week 36
Changes in Hemoglobin A1C
Tidsramme: week 0, week 6, week 12, week 24, week 36
HbA1C (mmol/mol) measures mean hemoglobin glycation over the previous three months.
week 0, week 6, week 12, week 24, week 36
Changes in Fasting Insulin
Tidsramme: week 0, week 6, week 12, week 24, week 36
High fasting insulin indicates the presence of insulin resistance. Exercise interventions can expect a small beneficial change in fasting insulin levels after 1-month of training.
week 0, week 6, week 12, week 24, week 36
Changes in Fasting Triglycerides
Tidsramme: week 0, week 6, week 12, week 24, week 36
A triglyceride level >150 mg/dL, is largely supported as an indicator of CVD risk. Exercise interventions can expect a small beneficial change in triglyceride levels following 1-month of training, even among people with normal triglyceride levels.
week 0, week 6, week 12, week 24, week 36
Changes in High-density Lipoprotein
Tidsramme: week 0, week 6, week 12, week 24, week 36
High-density lipoprotein (HDL; mg/dL) cholesterol is a predictor of future CVD among young and middle-aged people. Exercise interventions can expect a small effect after 1-month of training.
week 0, week 6, week 12, week 24, week 36
Changes in Low-density Lipoprotein
Tidsramme: week 0, week 6, week 12, week 24, week 36
Low-density lipoprotein (LDL; mg/dL) cholesterol is a predictor of future CVD among young and middle-aged people. Exercise interventions can expect a small effect after 1-month of training.
week 0, week 6, week 12, week 24, week 36
Changes in Total Cholesterol
Tidsramme: week 0, week 6, week 12, week 24, week 36
Total cholesterol (mg/dL) is a predictor of future CVD among young and middle-aged people. Exercise interventions can expect a small effect after 1-month of training.
week 0, week 6, week 12, week 24, week 36
Changes in Resting Systolic Blood Pressure
Tidsramme: week 0, week 6, week 12, week 24, week 36
Elevated blood pressure (mmHg) during childhood and adolescents is associated with intermediate markers and hard outcomes of CVD in adulthood. Moderate-intensity exercise is negatively associated with blood pressure. Small changes in blood pressure can occur from as early as 1-month of endurance training.
week 0, week 6, week 12, week 24, week 36
Changes in Resting Diastolic Blood Pressure
Tidsramme: week 0, week 6, week 12, week 24, week 36
Elevated blood pressure (mmHg) during childhood and adolescents is associated with intermediate markers and hard outcomes of CVD in adulthood. Moderate-intensity exercise is negatively associated with blood pressure. Small changes in blood pressure can occur from as early as 1-month of endurance training.
week 0, week 6, week 12, week 24, week 36
2-Minute Step Test
Tidsramme: Week 0, Week 6, Week 12, Week 24, Week 36
2 minute test is used to assess aerobic capacity by counting the number of steps an individual takes, hitting a target point, in 2 minutes. Individuals can hold on to supports for duration of the test. 2-minute step test will be for only ambulatory individuals. Higher number of steps in 2-minutes equates to higher aerobic capacity.
Week 0, Week 6, Week 12, Week 24, Week 36
Timed Up and Go (TUG)
Tidsramme: Week 0, Week 6, Week 12, Week 24, Week 36
TUG is a 3-meter walking test to assess an individuals functional balance and mobility. Individuals will start in a seated position, stand, walk 3-meters turning around a cone, walk back and sit down. Time will be measured in seconds, with lower time equating to higher functional balance and mobility.
Week 0, Week 6, Week 12, Week 24, Week 36
Hand-grip Strength Test (hand-held dynamometer)
Tidsramme: Week 0, Week 6, Week 12, Week 24, Week 36
Measure of isometric muscular strength of the hand and forearm. Using a hand-held dynamometer, individuals will hold onto device with arm supported at a 90 degree angle and squeeze as hard as they can for 3 seconds. Individuals will do 3 test on each hand, as able, with the average of the 3 attempt being their score. Hand-grip strength will be measured in kg, with higher values equating to more strength.
Week 0, Week 6, Week 12, Week 24, Week 36
NIH PROMIS Global Health Pediatric (7 item) survey
Tidsramme: Week 0, Week 6, Week 12, Week 24, Week 36
7-item survey assessing a child's self-reported health, including physical, mental, and social health. Each question is given a score of 1-5. The sum of all 7 questions will be used to determine the individuals total score which will be referenced to a z-score conversion table, with higher scores equating to better overall health.
Week 0, Week 6, Week 12, Week 24, Week 36
Changes in Body Weight
Tidsramme: Week 0,Week 6, Week 12, Week 24, Week 36
Body weight measured in lbs using a off-the-shelf bathroom scale.
Week 0,Week 6, Week 12, Week 24, Week 36

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Ledende efterforsker: Byron Lai, MS, PhD, University of Alabama at Birmingham

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. december 2026

Primær færdiggørelse (Anslået)

9. marts 2031

Studieafslutning (Anslået)

31. maj 2031

Datoer for studieregistrering

Først indsendt

27. april 2026

Først indsendt, der opfyldte QC-kriterier

27. april 2026

Først opslået (Faktiske)

4. maj 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

14. maj 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

11. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Andre undersøgelses-id-numre

  • IRB-300016599
  • UAB (Anden identifikator: UAB)

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-planbeskrivelse

All collected IPD.

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Cerebral parese (CP)

Kliniske forsøg med Extended Reality Exergaming

Abonner